INTRODUCTION
Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans is an oral bacterium that causes localized aggressive periodontitis (LAP), a rapidly progressing degenerative disease that occurs primarily in adolescent humans (38) . The disease results in loss of alveolar bone if left untreated. A. actinomycetemcomitans is also implicated in sub-acute infective endocarditis (3, 7), brain abscess formation, urinary tract infections and other systemic diseases in humans (15). The bacterium produces an array of virulence factors including an exotoxic leukotoxin (LtxA) which is a member of the repeats-in-toxin (RTX) family of bacterial cytolysins. There is evidence to suggest that highly leukotoxic strains of A. actinomycetemcomitans are more often associated with aggressive forms of periodontitis in humans than the minimally leukotoxic variants (4, 13, 14) . LtxA plays an important role in LAP pathogenesis by helping the bacterium destroy gingival crevice polymorphonuclear leukocytes (PMNs) and monocytes, resulting in the suppression of local immune defenses (1) . It lyses leukocytes, induces degranulation of PMNs, apoptosis in T lymphocytes and PMNs, releases proinflammatory cytokines from human macrophages (21, 26), and lyses erythrocytes (2) . There is also experimental evidence to Systems, San Jose, CA), and expressed as mean fluorescence intensity (MF1) (Fig. 2 ).
The parent cell line K562 cells, which do not express CD11a or CD18 antigen, was used as a negative control. Preparation of purified A. actinomycetemcomitans leukotoxin (LtxA). The LtxAs from strains JP2 (36) and NJ4500 (23) were produced, purified, verified for purity, and quantified as described previously (8, 19) . Experiments done to assess the potency of the two purified LtxA from strains JP2 and NJ4500 as measured by percent cytotoxicity and elevation of intracellular calcium ([Ca 2+ ] i ) using the HL-60 cell line, revealed that the LtxA of NJ4500 was more potent. Thus, all studies were done with the same batch of purified LtxA from strain NJ4500 of A. actinomycetemcomitans.
Determination of LtxA-induced intracellular calcium elevation. We used a previously described (18) video fluorescence imaging technique to quantify elevation of [Ca 2+ ] i in transductant cells exposed to LtxA (concentration of 2 g/ml). Briefly, cells were loaded with the fluorescent calcium indicator fura-2-acetoxymethyl (AM) ester as described previously (10), processed, attached to a coverslip, LtxA was added, and viewed on a The percent cytotoxicity was calculated using the formula described previously (11). The HL-60 and K562 cell lines served as controls. These results suggest that the human CD18 is the LtxA functional receptor.
Cysteine rich tandem repeats I-EGF-2, 3 and 4 of human CD18 are critical for species specific susceptibility of human leukocytes to LtxA. Results from FACS analysis indicate high levels of expression of CD18 antigen in all chimeric transductants, and expression levels were at comparable levels between different chimeric transductants ( Fig. 2) . Since preliminary experiments suggested that levels of expression markedly affected susceptibility to LtxA, all studies were done with transductants that expressed comparable high levels of expression of chimeric CD18 antigens. To locate the region within the human CD18 that is critical for susceptibility to the effects of LtxA, thirteen human x bovine chimeric constructs were generated and co-expressed with bovine CD11a in K562 cells. We surmised that chimeric CD18 made with different regions of human and bovine CD18 should identify the region within the CD18 that is critical for human CD18 into the corresponding region of bovine CD18 rendered the transductant expressing chimeric CD18 susceptible to LtxA-induced effects, it will indicate that the human CD18 fragment that was inserted is critical for susceptibility. As shown in Fig. 5 and 6, the chimeric transductants B200H, B400H, and H600B, showed marked susceptibility (as measured by elevation of [Ca 2+ ] i and cytotoxicity) to LtxA-induced effects, but not the transductants B600H, B700H, H400B and H500B. The above results indicate that the region that is critical for conferring susceptibility to the biological effects of LtxA resides between 500 to 600 amino acid residues of the extracellular region of human CD18. In an attempt to identify a smaller functional domain within this 100-amino acid residue region of human CD18 that is responsible for conferring species specific susceptibility to LtxA, we generated transductants in which individual I-EGF domains from human CD18 were switched with corresponding bovine sequences and vice versa.
In transductants which had the human CD18 backbone with individual bovine I-EGF domains inserted (H497B540H, H541B581H, and H582B617H), LtxA elicited its biological effects ( Fig.5 and 6 ). By contrast, transductants which had the bovine CD18 backbone with individual human I-EGF domains inserted (B497H540B, B541H581B, and B582H617B) were not susceptible to the effects of LtxA. These results suggest that the entire and not any individual I-EGF domain in this region of the human CD18 is critical for conferring species specific susceptibility to LtxA effects. In addition, these results suggest that susceptibility to LtxA cannot be attributed to individual I-EGF domains of human CD18, but rather to a larger region encompassing all three I-EGF domains. B400H : N-terminal 400 amino acids of human CD18 were replaced with bovine CD18; B600H : N-terminal 600 amino acids of human CD18 were replaced with bovine CD18; B700H : the entire extracellular domain of human CD18 replaced with bovine CD18 ; H400B: N-terminal 400 amino acids of bovine CD18 were replaced with human CD18; H500B: N-terminal 500 amino acids of bovine CD18 were replaced with human CD18; H600B: N-terminal 600 amino acids of bovine CD18 were replaced with human CD18; H497B540H: EGF-2 domain (aa residues 497-540) of human CD18 was replaced corresponding sequences from bovine CD18; B497H540B: EGF-2 domain (aa residues 497-540) of bovine CD18 was replaced corresponding sequences from human CD18; H541B581H; EGF-3domain (aa residues 541-581) of human CD18 was replaced corresponding sequences from bovine CD18; B541H581B; EGF-3domain (aa residues 541-581) of bovine CD18 was replaced corresponding sequences from human CD18; H582B617H; EGF-3domain (aa residues 582-617) of human CD18 was replaced corresponding sequences from bovine CD18; H582B617H; EGF-3domain (aa residues 582-617) of bovine CD18 was replaced corresponding sequences from human CD18; The figure also shows schematic depiction of the BoCD18 and HuCD18 amino acids. 
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